GlassScriptPhysician profile
William Elliotte Pearson
NPI 1972758480
$2,053.88
in general payments reported to CMS, 2019-2025
17 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $577 · 2023: $361 · 2024: $372 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $408.17 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $363.57 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $334.93 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $207.06 | 2022-2024 | Zepbound, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $162.07 | 2021-2022 | |
| Insulet Corporation | $128.88 | 2024-2025 | Omnipod |
| Abbott Laboratories | $71.19 | 2021-2025 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $69.21 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $59.37 | 2022-2025 | |
| Exact Sciences Corporation | $56.72 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $54.96 | 2021-2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.63 | 2022-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $28.83 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.82 | 2025 | Jardiance |
| Dexcom, INC. | $17.42 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $13.86 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.